Tributyrin induces differentiation, growth arrest and apoptosis in androgen-sensitive and androgen-resistant human prostate cancer cell lines

International Journal of Cancer

Volumn 88, Issue 2, 2000, Pages 245-251

  Maier, Simone ^a   Reich, Ella ^a   Martin, Renate ^a   Bachem, Max ^a   Altug, Vedat ^a   Hautmann, Richard E ^a   Gschwend, Jürgen E ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; BUTYRIC ACID; PROSTATE SPECIFIC ANTIGEN; TRIBUTYRIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CELL CYCLE; CELL DIFFERENTIATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; QUALITY OF LIFE;

ANDROGENS; APOPTOSIS; BUTYRATES; CELL CYCLE; CELL DIFFERENTIATION; CELL DIVISION; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HUMAN; MALE; PROSTATIC NEOPLASMS; SUPPORT, NON-U.S. GOV'T; TRIGLYCERIDES; TUMOR CELLS, CULTURED;

EID: 0033819161     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(20001015)88:2<245::AID-IJC16>3.0.CO;2-X     Document Type: Article

References (25)

1. Butyrate rapidly induces growth inhibition and differentiation in HT-29 cells
2. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated localized prostate cancer
3. Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate
4. p53 Oncogene mutations in three human prostate cancer cell lines
5. Tributyrin: A prodrug of butyric acid for potential clinical application in differentiation therapy
6. Phase I study of the orally administered butyrate prodrug tributyrin in patients with solid tumors
7. Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and rats
8. Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model
9. Sodium butyrate induces apoptosis in human colonic tumor cell lines in a p53 independent pathway: Implications for the possible role of dietary fiber in the prevention of large bowel cancer
10. Initiation of growth arrest and apoptosis of MCF-7 mammary carcinoma cells by tributyrin, a triglyceride analogue of the short-chain fatty acid butyrate, is associated with mitochondrial activity
11. LNCaP model of human prostatic cancer
12. Establishment of a new prostatic carcinoma cell line (TSU-Pr1)
13. Establishment and characterization of human prostatic carcinoma cell line (PC-3)
14. Clinical pharmacology of sodium butyrate in patients with acute leukemia
15. Review letter: Butyrate as a differentiating agent: Pharmacokinetics, analogues and current status
16. Butyrates and phenylacetate as differentiating agents: Practical problems and opportunities
17. Effect of polar organic compounds on leukemic cells. Butyrate-induced partial remission of acute myelogenous leukemia in a child
18. Cancer statistics by race and ethnicity
19. Differential elimination of synthetic butyric triglyzerides in vivo: A pharmacokinetic study
20. Phenylacetate: A novel nontoxic inducer of tumor cell differentiation
21. Tributyrin induces growth inhibitory and differentiating effects on HAT-29 colon cancer cells in vitro
22. The absorption of short-chain fats by premature infants
23. Potentiation of retinoic acid-induced differentiation of human acute promyelocytic leukemia NB4 cells by butyric acid, tributyrin, and hexamethylene bisacetamide
24. Failure of programmed cell death and differentiation as causes of tumors: Some simple mathematical models
25. Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors